General
Preferred name
miransertib
Synonyms
ARQ-092 ()
AKT inhibitor 2 ()
ARQ-092 trihydrochloride ()
ARQ 092 ()
Miransertib (hydrochloride) ()
ARQ-092 (hydrochloride) ()
Miransertib hydrochloride ()
Miransertib (ARQ 092) HCl ()
Miransertib (ARQ-092) ()
ARQ 092 FREE BASE ()
ARQ092 ()
Miransertib mesylate ()
ARQ092 FREE BASE ()
ARQ-092 MESYLATE ()
Miransertib bismesylate ()
ARQ 092 mesylate ()
Miransertib dimesylate ()
Miransertib trihydrochloride ()
P&D ID
PD053553
CAS
1313881-70-7
1817727-87-9
1313883-00-9
Tags
available
drug candidate
Drug indication
Proteus syndrome
Lymphoma
Neoplasm
Solid tumour/cancer
Drug Status
investigational
Max Phase
2.0
1.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION ARQ-092 is an orally active, selective, and potent allosteric AKT inhibitor , being developed for antineoplastic potential.
DESCRIPTION Miransertib (ARQ-092) is an orally active, selective, and potent allosteric AKT inhibitor , being developed for antineoplastic potential. (GtoPdb)
DESCRIPTION Miransertib (ARQ-092) is a potent, orally active, selective and allosteric Akt inhibitor with IC50s of 2.7 nM, 14 nM and 8.1 nM for Akt1, Akt2, Akt3, respectively. Miransertib is also a potent the AKT1-E17K mutant protein inhibitor and has the potential for PI3K/AKT-driven tumors and Proteus syndrome research[1]. Miransertib is effective against Leishmania[2].
PRICE 152
DESCRIPTION Miransertib hydrochloride (ARQ-092 hydrochloride) is a potent, orally active, selective and allosteric Akt inhibitor with IC50s of 2.7 nM, 14 nM and 8.1 nM for Akt1, Akt2, Akt3, respectively. Miransertib hydrochloride is also a potent the AKT1-E17K mutant protein inhibitor and has the potential for PI3K/AKT-driven tumors and Proteus syndrome research[1]. Miransertib hydrochloride is effective against Leishmania[2].
DESCRIPTION Miransertib (ARQ-092) is an orally bioavailable, selective, and potent allosteric Akt inhibitor. (TargetMol Bioactive Compound Library)
DESCRIPTION Miransertib is an orally bioavailable and selective AKT pathway inhibitor that suppresses AKT1, 2, 3 isoforms. It binds to both the active and inactive forms of AKT. Miransertib inhibits PIK3CA/AKT1 mutant dependent kinase signaling and exhibits antitumor activity. (BOC Sciences Bioactive Compounds)
DESCRIPTION Miransertib is a potent, orally active, selective and allosteric Akt inhibitor. Miransertib is effective against Leishmania. (Enamine Bioactive Compounds)
Cell lines
5
Organisms
0
Compound Sets
16
AdooQ Bioactive Compound Library
A16286
BOC Sciences Bioactive Compounds
miransertib-hydrochloride-cas-1313883-00-9-291560
Cayman Chemical Bioactives
21388
ChEMBL Drugs
CHEMBL4297188
CHEMBL4298151
Drug Repurposing Hub
DrugBank
DB14982
DrugMAP
DM5WK0J
Enamine Bioactive Compounds
EBC-191026
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS100462
Guide to Pharmacology
9429
MedChem Express Bioactive Compound Library
HY-19719
HY-19719A
PKIDB
ReFrame library
Selleckchem Bioactive Compound Library
miransertib
arq-092
TargetMol Bioactive Compound Library
T3467
External IDs
32
Properties
(calculated by RDKit )
Molecular Weight
432.21
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
2
Rotatable Bonds
4
Ring Count
6
Aromatic Ring Count
5
cLogP
5.07
TPSA
95.64
Fraction CSP3
0.15
Chiral centers
0.0
Largest ring
6.0
QED
0.41
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Akt
Parasite
AKT2
MOA
Akt inhibitor
Pathway
Cytoskeletal Signaling
Microbiology/virology
PI3K/Akt/mTOR signaling
Anti-infection
PI3K/Akt/mTOR
Source data